[{"address1": "2 Blue Hill Plaza", "address2": "3rd Floor", "city": "Pearl River", "state": "NY", "zip": "10965", "country": "United States", "phone": "914 347 4300", "fax": "914 347 4560", "website": "https://www.acorda.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.", "fullTimeEmployees": 102, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ron  Cohen M.D.", "age": 67, "title": "Founder, CEO, President & Director", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": 984150, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael A. Gesser M.B.A.", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 459150, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kerry M. Clem", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 592225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Morales", "age": 55, "title": "Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Felicia  Vonella", "title": "Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil S. Belloff Esq.", "age": 63, "title": "General Counsel & Corporate Secretary", "yearBorn": 1960, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tierney  Saccavino", "title": "Executive Vice President of Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Denise J. Duca", "title": "Executive Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Mayer J.D.", "title": "Senior Vice President", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Sofia  Ali", "title": "Senior VP of Operations & Strategic Planning", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.661, "open": 0.75, "dayLow": 0.661, "dayHigh": 0.661, "regularMarketPreviousClose": 0.661, "regularMarketOpen": 0.75, "regularMarketDayLow": 0.661, "regularMarketDayHigh": 0.661, "beta": 1.462, "forwardPE": -0.6885417, "volume": 321668, "regularMarketVolume": 321668, "averageVolume": 132290, "averageVolume10days": 800704, "averageDailyVolume10Day": 800704, "marketCap": 821028, "fiftyTwoWeekLow": 0.25, "fiftyTwoWeekHigh": 24.196, "priceToSalesTrailing12Months": 0.006979572, "fiftyDayAverage": 11.411182, "twoHundredDayAverage": 13.077067, "currency": "USD", "enterpriseValue": 161447136, "profitMargins": -2.14952, "floatShares": 1215467, "sharesOutstanding": 1242100, "sharesShort": 8102, "sharesShortPriorMonth": 11084, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0064999997, "heldPercentInsiders": 0.0068900003, "heldPercentInstitutions": 0.13223, "shortRatio": 1.84, "shortPercentOfFloat": 0.0066000004, "impliedSharesOutstanding": 1731030, "bookValue": -127.169, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -252854000, "trailingEps": -203.57, "forwardEps": -0.96, "lastSplitFactor": "1:20", "lastSplitDate": 1685923200, "enterpriseToRevenue": 1.372, "enterpriseToEbitda": 19.215, "52WeekChange": -0.95733124, "SandP52WeekChange": 0.23416412, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ACOR", "underlyingSymbol": "ACOR", "shortName": "Acorda Therapeutics, Inc.", "longName": "Acorda Therapeutics, Inc.", "firstTradeDateEpochUtc": 1139581800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6677f3ed-ce73-34bc-a776-76e782fb0960", "messageBoardId": "finmb_24246", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.661, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 29979000, "totalCashPerShare": 24.136, "ebitda": 8402000, "totalDebt": 190896992, "quickRatio": 0.208, "currentRatio": 0.328, "totalRevenue": 117633000, "revenuePerShare": 94.713, "returnOnAssets": -0.05768, "freeCashflow": 20144876, "operatingCashflow": -13984000, "revenueGrowth": 0.207, "grossMargins": 0.82628, "ebitdaMargins": 0.07143, "operatingMargins": 0.03899, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-13"}]